

Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

Information for the public

Published: 21 May 2026

www.nice.org.uk

Osimertinib (Tagrisso) is available on the NHS as a possible treatment for unresectable locally advanced (stage 3) non-small-cell lung cancer in adults when:

- the tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and
- the cancer has not progressed (got worse) during or after platinum-based chemoradiotherapy.

Locally advanced means the cancer has spread to nearby tissues. Unresectable means it cannot be removed with surgery.

If you are not eligible for osimertinib but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on lung cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [EGFR Positive UK](#), contact@egfrpositive.org.uk
- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](#), 01675 477607
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9513-4